key: cord-0727410-2pw6958t
authors: Li, Zhe; Lin, Yuxi; Huang, Yi-You; Liu, Runduo; Zhan, Chang-Guo; Wang, Xin; Luo, Hai-Bin
title: Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors
date: 2021-02-23
journal: Proc Natl Acad Sci U S A
DOI: 10.1073/pnas.2024937118
sha: 09dc334e6c9151186e1ee963176edf503f8ac92c
doc_id: 727410
cord_uid: 2pw6958t

nan

and Wang (1) tested our recently reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro ) noncovalent inhibitors (2) using their in vitro assays, and they obtained negligible or much lower inhibitory activities compared to ours. Knowing the discrepancy, we first carefully rechecked our original experimental records, and we did not find any potential concern with our data that had been repeated by multiple coauthors. Notably, the fluorescence resonance energy transfer (FRET)-based enzymatic assay used by Ma and Wang (1) is different from our FRETbased enzymatic assay in the M pro protein (discussed below) and the FRET substrate [longer than the more popularly used substrate (3, 4) utilized in our assay].

Particularly for M pro , Ma and Wang (1) incorrectly state that a GST-tagged M pro was used in our assay. Actually, as described in our paper (2), the GST tag was cleaved with thrombin; the GST tag was used only for conveniently isolating M pro from the culture medium. So, the M pro protein used in our assay is the true wild-type M pro with native N and C termini. In comparison, the FRET-based enzymatic assay described by Ma et al. (5) used a C-terminal His-tagged M pro protein.

As noted correctly by Ma and Wang (1), M pro requires a native N terminus to form the enzymatically active dimer. In fact, both the N and C termini of M pro are very close to the active-site cavity in the dimer according to available X-ray crystal structures (Protein Data Bank [PDB] ID code 7BUY) (6), including one (PDB ID code 6WTT) shown by Ma et al. (5) . Thus, an additional tag on the N or C terminus could interfere with M pro binding with a ligand (substrate or inhibitor). So, a given ligand could have a lower binding affinity with the His-tagged M pro .

In fact, we obtained Michaelis constant (K m ) = 1.41 μM (Fig. 1) for the M pro protein without any tag, and our reported catalytic efficiency (2) is close to the previously reported value (catalytic constant k cat /K m = 28,500 M −1 ·s −1 ) (4). However, K m = 28.2 μM for the His-tagged M pro (5) . So, the His-tagged M pro has a ∼20-fold lower binding affinity with the substrate compared to the tag-free M pro . In other words, the activity determined by using the assay with a His-tagged M pro might not reflect the actual activity with native M pro .

Ma and Wang (1) also used native mass spectrometry (MS) and thermal shift assays (TSA) to detect the protein-ligand binding. For binding driven by hydrophobic interaction the protein-ligand complex will most likely dissociate in MS (7) . For TSA, false negatives are also known to occur (8, 9) . Both assays might not be suitable for analyzing noncovalent inhibitors of M pro .

Finally, GC-376, a covalent inhibitor identified in their earlier reports, was used as a positive control to validate their assays by Ma and Wang (1). However, it is difficult to understand why their results show halfmaximum inhibitory concentration (IC 50 ) = 28 or 33 nM when the enzyme concentration was 100 nM. Their data, if validated, would imply that each GC-376 molecule inactivated multiple M pro protein molecules through an unusual mechanism.

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

Native mass spectrometry in fragment-based drug discovery

Efficiency of hit generation and structural characterization in fragment-based ligand discovery

Tracking cancer drugs in living cells by thermal profiling of the proteome

Lys-NH2 at various concentrations. (A) Original data obtained. (B) Lineweaver-Burk plot used to determine the catalytic parameters. 2 of 2